Anticholinergic Drugs in urology
Reading File
Reading File
Finding Sources
Searching PubMed
"overactive bladder" AND antimuscarinic
Searching the Web
AUA SUFU guideline idiopathic overactive bladder antimuscarinic statements cognitive risk
Finding Sources
Finding Sources
Reading Web Page
https://www.auanet.org/guidelines-and-quality/guidelines/idi…
Reading Article
PMID: 41686541
Reading File
Reading File
Reading File
Anticholinergic drugs in urology
In urology, “anticholinergics” usually means antimuscarinic drugs used to suppress involuntary detrusor contractions and improve bladder storage.
Mechanism
They competitively block muscarinic receptors, mainly M3 receptors, in the detrusor muscle.
Effects
- Relaxes detrusor during the storage phase
- Reduces urgency, frequency, nocturia, and urge urinary incontinence
- Increases functional bladder capacity
- Lowers intravesical pressure, especially important in neurogenic bladder
Although M2 receptors are more numerous in the bladder, M3 receptors are more functionally important for contraction and relaxation. - Smith and Tanagho's General Urology, p. 492
Main indications
-
Idiopathic overactive bladder (OAB)
- Urinary urgency, usually with frequency and nocturia, with or without urgency urinary incontinence.
- The AUA/SUFU guideline recommends either an antimuscarinic or a beta-3 agonist to improve urgency, frequency, and urge incontinence. AUA/SUFU OAB guideline
-
Urgency urinary incontinence
-
Neurogenic detrusor overactivity / neurogenic bladder
- For example, spinal cord injury, multiple sclerosis, spina bifida.
- Often combined with clean intermittent catheterization when emptying is impaired.
-
Nocturnal enuresis
- Oxybutynin may be used in selected children with demonstrable detrusor overactivity or reduced bladder capacity, usually not as isolated first-line treatment.
Common drugs
| Drug | Useful features |
|---|---|
| Oxybutynin | Widely used; oral immediate-release and extended-release, transdermal patch, topical gel. Higher dry-mouth and CNS burden, especially immediate-release oral form. |
| Tolterodine | IR and ER preparations; intended to have relative bladder selectivity clinically. |
| Solifenacin | Relatively M3-selective; usually once daily. |
| Darifenacin | Relatively M3-selective; usually once daily. |
| Fesoterodine | Prodrug related to tolterodine; once daily. |
| Trospium | Quaternary ammonium compound with low blood-brain barrier penetration, often a reasonable option when CNS effects are a concern. |
| Propiverine | Used in some countries; has antimuscarinic and calcium-channel blocking actions. |
Oxybutynin, darifenacin, fesoterodine, solifenacin, tolterodine, and trospium are standard synthetic antimuscarinic options for OAB. They reduce intravesical pressure and contraction frequency while increasing bladder capacity. - Lippincott Illustrated Reviews: Pharmacology, p. 184
Adverse effects
These arise from muscarinic blockade outside the urinary tract:
- Dry mouth - most frequent
- Constipation
- Blurred vision and dry eyes
- Tachycardia or palpitations
- Reduced sweating and heat intolerance
- Dyspepsia
- Difficulty voiding, increased post-void residual, or urinary retention
- Confusion, memory impairment, delirium, and falls, particularly in frail older adults or those with a high total anticholinergic burden
Extended-release and transdermal oxybutynin generally cause fewer systemic adverse effects than oral immediate-release oxybutynin. - Lippincott Illustrated Reviews: Pharmacology, p. 184
Contraindications and major cautions
Avoid or use only with specialist guidance in:
- Urinary retention or significant bladder outlet obstruction
- Raised post-void residual
- Uncontrolled narrow-angle glaucoma
- Gastric retention, severe constipation, or markedly impaired gastric emptying
- Myasthenia gravis
- Frail older adults, dementia, delirium risk, or substantial polypharmacy
The AUA/SUFU guideline specifically advises extreme caution with narrow-angle glaucoma, impaired gastric emptying, and a history of urinary retention. It also advises discussing possible cognitive impairment and dementia risk before prescribing these drugs. Guideline pharmacotherapy statements
Practical selection points
- Start with behavioral care as appropriate: bladder training, fluid and caffeine review, timed voiding, and pelvic-floor therapy.
- Assess urinalysis and consider post-void residual before treatment when retention or obstruction is possible.
- In older adults, minimize total anticholinergic burden. Trospium, darifenacin, or fesoterodine may have less theoretical CNS exposure than agents that more readily cross the blood-brain barrier.
- If dry mouth, constipation, cognitive concerns, or retention make an antimuscarinic unsuitable, consider a beta-3 agonist such as mirabegron or vibegron, subject to the patient’s cardiovascular profile and local prescribing guidance.
- In men with both BPH-associated lower urinary tract symptoms and OAB, an antimuscarinic can sometimes be combined with an alpha-blocker, but residual urine and retention risk need attention.
Important current evidence note
Long-term cognitive risk is not fully settled, but it should not be ignored. A 2026 systematic review in older women found no significant short-term cognitive effect in small RCTs, while observational studies showed an association with later cognitive decline or dementia. The authors judged the underlying evidence vulnerable to bias, so this is an association rather than proof of causation. Maguire et al., 2026, PMID 41686541
Exam summary:
Antimuscarinics block M3 receptors in the detrusor, increasing bladder capacity and reducing urgency/urge incontinence. Main adverse effects are dry mouth, constipation, blurred vision, cognitive effects, and urinary retention.
Antimuscarinics block M3 receptors in the detrusor, increasing bladder capacity and reducing urgency/urge incontinence. Main adverse effects are dry mouth, constipation, blurred vision, cognitive effects, and urinary retention.
Where does m3 receptors present
Reading File
Finding Sources
Searching PubMed
"M3 muscarinic receptor" distribution
Searching the Web
M3 muscarinic receptor tissue distribution smooth muscle glands endothelium pharmacology
M3 muscarinic receptors are present mainly on:
- Bladder detrusor smooth muscle - causes detrusor contraction and voiding
- Bronchial smooth muscle - causes bronchoconstriction
- Gastrointestinal smooth muscle - increases gut motility and contractions
- Iris sphincter muscle - causes miosis
- Ciliary muscle of the eye - accommodation for near vision
- Exocrine glands - salivary, lacrimal, bronchial, and sweat glands, increasing secretion
- Gastric parietal cells - promotes gastric acid secretion
- Vascular endothelium - stimulates nitric oxide release, causing vasodilation
Signal pathway: M3 is Gq-coupled → activates phospholipase C → IP3/DAG → raises intracellular Ca²⁺.
In urology, M3 receptors in the detrusor are primarily responsible for bladder contraction. Therefore, antimuscarinic drugs block M3 action to reduce urgency and urge incontinence. - Campbell-Walsh-Wein Urology, Muscarinic Receptors section
Diseases in urology
Reading File
Urology covers conditions of the kidneys, ureters, bladder, prostate, urethra, testes, and male reproductive system.
- Urinary infections - cystitis, pyelonephritis, prostatitis, urethritis
- Urinary stones - kidney, ureteric, and bladder calculi
- Obstructive diseases - benign prostatic hyperplasia (BPH), urethral stricture, pelvi-ureteric junction obstruction
- Lower urinary tract disorders - overactive bladder, urinary incontinence, urinary retention, neurogenic bladder
- Urological cancers - renal cell carcinoma, bladder cancer, prostate cancer, testicular cancer, penile cancer
- Male reproductive disorders - erectile dysfunction, infertility, varicocele, hydrocele, epididymo-orchitis
- Scrotal emergencies - testicular torsion, Fournier gangrene
- Congenital urology - posterior urethral valves, vesicoureteral reflux, hypospadias, undescended testis
- Trauma - renal, bladder, urethral, and testicular trauma
- Renal and urinary tract tuberculosis / parasitic disease
The main clinical presentations are flank pain, dysuria, fever, hematuria, lower urinary tract symptoms, incontinence, scrotal swelling, and infertility. Some require urgent treatment, particularly sepsis with obstruction, testicular torsion, acute urinary retention, Fournier gangrene, and major trauma.
Asking for Preferences
Which urology topic would you like explained in detail?
This is a shared conversation. Sign in to Orris to start your own chat.